EGFR and lung cancer: Although the emergence of EGFR-TKIs has brought a revolutionary breakthrough in the treatment of lung cancer, the disease still progresses after 9–11 months of treatment with EGFR-TKIs (Fukuoka et al., 2011; Rosell et al., 2012).